Iris Y Navarro-Millán, MD

Iris-NavarroAssistant Professor of Medicine
Division of Clinical Immunology & Rheumatology

Address: 
 

Faculty Office Tower, room 850
510 20th Street South
35294-2182

Telephone: (205) 996-5602
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Education

 
BS (Biology), University of Puerto Rico-Mayaguez-Campus, Mayaguez, Puerto Rico, 2001
MD, Universidad Autónoma de Guadalajara School of Medicine, Guadalajara, Jalisco,   Mexico, 2005
Residency (Internal Medicine), Baptist Health System, Birmingham, Alabama, 2008-2009
Residency (Internal Medicine), Carraway Methodist Medical Center, Birmingham, Alabama, 2006-2008
Clinical Fellowship (Rheumatology),
University of Alabama at Birmingham, Birmingham, Alabama, 2009-2011
Postdoctoral Fellowship, Outcomes and Comparative Effectiveness, University of Alabama at Birmingham, 2010-2012


Research and Clinical Interests

 
Dr. Navarro-Millán’s area of interest is epidemiology and comparative effectiveness in rheumatic diseases, especially in patients with rheumatoid arthritis. Dr. Navarro-Millán has ongoing projects that include evaluating various aspects of the prevalence, risk factors, and durability of remission in RA using the new American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission. Dr. Navarro-Millán is also interested in determining the role of traditional cardiovascular risk factors in coronary heart disease outcomes in patients with rheumatoid arthritis.

Another area of interest for her is to understand the relationship between the clinical and molecular factors that influence the development of complex diseases such as rheumatoid arthritis and other rheumatic diseases and develop prediction models for disease outcomes in RA and other rheumatic diseases using clinical data.


Selected Publications

 

Navarro-Millán I, Chen L, Greenberg JD, Pappas DA, Curtis JR. 2013. Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. Semin Arthritis Rheum. 2013 Jun 3. doi:pii: S0049-0172(13)00022-X. 10.1016/j.semarthrit.2013.02.002. [Epub ahead of print] PMID:23742957

 

Curtis JR, McVie T, Mikuls TR, Reynolds RJ, Navarro-Millán I, O'Dell J, Moreland LW, Bridges SL Jr, Ranganath VK, Cofield SS. 2013. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial. J Rheumatol. 40(5):572-8. PMID:23588939 Free PMC Article

 

Navarro-Millán I, Curtis JR. 2013. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol. 25(3):384-90. PMID:23511719

 

Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR. 2013. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 65(6):1430-8. PMID:23460074  PMCID:PMC3672346

 

Navarro-Millán I, Singh JA, Curtis JR. 2012. Systematic review of ocilizumab for Rheumatoid Arthritis: A New Biologic Targeting the Interleukin-6 Receptor. Clnl Ther 34(4):788-802.e3 PMID: 22444783

 

Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, Navarro-Millán I, Kavanaugh A. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2011 Oct 13. PMID: 21998118.

 

Curtis JR, Chen L, Luijtens K, Navarro-Millán I, Goel N, Gervitz L, Weinblatt M: Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum. 2011 Aug;63(8):2203-8. PMID: 21484766.

 

 

 
 
 

SOM Epilogue Menu